Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II Study of TAS-117 in combination with futibatinib in advanced solid tumors
jRCT2080224785Phase 2Completed
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Jul 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pifusertib and futibatinib in Nonhematologic neoplasms, Pulmonary squamous cell carcinoma and cancer, sponsored by Taiho Pharmaceutical Co., Ltd. Primary endpoints: Maximum tolerated dose (MTD) of TAS-117 in combination with futibatinib and Recommended dose (RD) of TAS-117 in combination with futibatinib. Started Jul 2019; status: completed.
02
Drugs
pifusertibfutibatinib
03
Conditions
Nonhematologic neoplasmsPulmonary squamous cell carcinomacancer
Beyond the preview
Go deeper on jRCT2080224785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224785.